透過您的圖書館登入
IP:3.141.152.173
  • 學位論文

穀胱甘肽調控之矽金奈米複合載體 於細胞內藥物釋放之應用

Glutathione-Tunable Intracellular Drug Delivery by Thin Layer Silica-Au Nanoconjugates

指導教授 : 許馨云

摘要


現今醫學發達,在治療腫瘤或癌症時,經常使用化學療法來達到其治癒目的。而在化學療法的過中,對於系統的載藥量、選擇性與否以及在不同的時間、環境下,可用人為方式順利控制藥物的釋放情形,是當今在化學療法領域中的一大挑戰。抗癌藥物容易對體內臟器產生累積性的傷害而致命,因而限制了藥物的多次使用,故必須發展高度選擇性探針,以便能將化療藥物精確帶到目標細胞位置,減少藥物對人體造成的毒副作用。 本研究開發穀胱甘肽調控之一新穎矽金奈米複合藥物載體 Transferrin-FITC-ReSi-Au NPs,將具有雙硫鍵結的矽材料(ReSi)修飾於金奈米表面,並藉由胺基將模擬藥物異硫氰酸螢光(Fluorescein isothiocyanate, FITC)修飾於藥物載體上,除此之外,更於藥物載體上加入運鐵蛋白(Transferrin protein),其對於人類肝癌細胞(Hep G2)的表面特定的接收器(transferrin receptor)有良好親和性,藉由胞飲作用,藥物載體得以運送進入癌症細胞,致使高濃度的榖胱甘肽還原載體內之雙硫鍵網狀結構,進而在細胞體內誘發藥物釋放,達到標靶治療的目的。

並列摘要


Nanobiotechnology has been recognized as an emerging field with great potential to provide considerably sensitive diagnostics and therapeutics for human diseases. The construction of stimuli-responsive, controlled-release systems for intracellular drug delivery is of crucial importance in practice to improve the healthcare of patients. In this study, we design a glutathione (GSH)-tunable intracellular drug delivery system. The surface of gold nanoparticles (Au NPs, 13-nm) was assembled with a novel silica-based material ReSi (redox-responsive silica), composed by the dithiobis(succinimidyl propionate) and (3-aminopropyl) trimethoxysilane networks. Fluorescein isothiocyanate (FITC) was chosen as a model drug and covalently modified on the surface of ReSi-Au NPs. The disulfide bond in ReSi were sensitive to GSH-gradient (1 mM-10 mM) in cells and the structure could be degraded within 1 hour. Moreover, redox-responsive drug release could be monitored in situ by tracing the sites where fluorescence recovery and Au NPs aggregation occurred due to the destruction of disulfide-bonded networks. We expect such nanoconjugate to serve both as a drug carrier and as an optical probe for cancer theranostics.

參考文獻


[7] Y.-C. Chen, X.-C. Huang, Y.-L. Luo, Y.-C. Chang, Y.-Z. Hsieh, H.-Y. Hsu, Science and Technology of Advanced Materials, 14 (2013) 044407.
[10] J. Kost, R. Langer, Advanced Drug Delivery Reviews, 64, Supplement (2012) 327-341.
[11] V.P. Torchilin, Advanced Drug Delivery Reviews, 64, Supplement (2012) 302-315.
[12] E. Fleige, M.A. Quadir, R. Haag, Advanced Drug Delivery Reviews, 64 (2012) 866-884.
[14] C.M. Cobley, L. Au, J. Chen, Y. Xia, Expert Opinion on Drug Delivery, 7 (2010) 577-587.

延伸閱讀